What drugs does MSN make?

MSN has 99 FDA-approved drugs including OLUMIANT, SACUBITRIL AND VALSARTAN, LINAGLIPTIN AND METFORMIN HYDROCHLORIDE.

What therapeutic areas does MSN focus on?

MSN focuses primarily on Oncology and Cardiovascular and 1 other therapeutic areas.

← Back

Data updated: Jul 17, 2026

MSN

Generics

Oncology Cardiovascular Neurology

MSN is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology. Key products include OLUMIANT.

2017

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

FDA Novel Drug Designations

(2018)

1 Novel

See 1 novel approval →

2018 OLUMIANT (BARICITINIB)

MSN's Key Drugs

MSN's core commercial portfolio centers on OLUMIANT, SACUBITRIL AND VALSARTAN, LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.

OLUMIANT

Immunology

Rheumatoid Arthritis

JAK1 Approved 2018

SACUBITRIL AND VALSARTAN

Cardiovascular

Heart Failure

AT1 receptor Approved 2024

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

Type 2 Diabetes

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

Metabolic

Approved 2026

MSN's Recent FDA Approvals

MSN secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

PYRIDOSTIGMINE BROMIDE NDA

2024-10-04

pyridostigmine bromide

INDICATIONS AND USAGE Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.

BORTEZOMIB NDA

2024-08-26

bortezomib

MSN's Therapeutic Areas

MSN's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 31%

12 drugs

Cardiovascular 28%

11 drugs

Neurology 21%

8 drugs

Gastroenterology 10%

4 drugs

Respiratory 10%

4 drugs

MSN's Top Competitors

MSN's closest competitors by therapeutic-area and drug-target overlap include Novartis, GE HEALTHCARE, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma

Oncology, Cardiovascular, Respiratory

GE HEALTHCARE specialty

Neurology, Cardiovascular, Oncology, Respiratory

Merck big-pharma

Oncology, Cardiovascular, Respiratory

AZURITY specialty

Cardiovascular, Oncology, Neurology, Respiratory

Bayer big-pharma

Oncology, Cardiovascular, Respiratory